Errol De Souza, Ph.D., President and Chief Executive Officer
Errol brings executive-level biotechnology and pharmaceutical expertise to Archemix. He joined the Company as President and Chief Executive Officer in April 2003, having led Synaptic Pharmaceutical Corp. until its sale to H. Lundbeck A/S of Denmark. Prior to joining Synaptic, Errol served as Senior Vice President and Head of Global Lead Generation for Hoechst Marion Roussel, and was appointed Senior Vice President and U.S. Head of Drug Innovation and Approval following the company's merger with Rhône-Poulenc to form Aventis. He was previously the Co-Founder and Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. He has also served as Director of Central Nervous System Diseases Research at the Du Pont Merck Pharmaceutical Company. Errol has held several academic positions and currently serves as a Professor for the Center for Molecular and Behavioral Neuroscience at Rutgers University. He has edited five books and authored numerous scientific articles, reviews and chapters. His research has focused on the receptor mechanisms involved in coordinating brain-endocrine-immune responses to stress. Errol has served on several editorial boards and National Institutes of Health (NIH) committees. He earned a Ph.D. in Endocrinology and a B.A. in Physiology from the University of Toronto. 
Duncan Higgons, M.Sc., Executive Vice President, Business Operations
Duncan joined Archemix in February 2006 as Executive Vice President, Business Operations. He is an industry leader with over 23 years of commercial experience in pharmaceuticals and biotechnology. Duncan has broad responsibility for providing leadership and strategic direction to Archemix's business development, project management, human resources, legal affairs, and overall corporate strategy. Prior to joining Archemix, he was Chief Commercial Officer for TransForm Pharmaceuticals, a privately held biotechnology company that was acquired by Johnson & Johnson. At TransForm, he was responsible for the continued development and expansion of all commercialization initiatives, including business development, corporate strategy and product development. Duncan previously served as Senior Vice President, Business Development and Marketing for Alkermes, Inc. In this role, he managed a broad range of functions, including new product identification, portfolio planning and business development. Prior to Alkermes, Duncan held senior management positions at Eli Lilly and Co. and Baxter International, Inc. Duncan is a graduate of King's College, University of London, and earned a M.Sc. from London Business School, where the faculty selected him for an Exchange Scholarship to the Wharton Graduate School at the University of Pennsylvania. 
Gregg Beloff, J.D., Chief Financial Officer
Gregg brings expertise in financial management, regulatory compliance, mergers and acquisitions, and fundraising to his post as Chief Financial Officer at Archemix. During his career, Gregg has worked both in industry and in the capital markets in the life sciences sector. Before joining Archemix in December 2003, he served as Chief Financial Officer for ImmunoGen, a $200 million publicly traded biotechnology company. Previously, Gregg worked as an investment banker, serving as a Vice President in Healthcare Investment Banking at Adams, Harkness & Hill, Inc. Prior to attending business school, Gregg practiced corporate law in Boston at the law firm of Gaffin & Krattenmaker, P.C. Gregg holds a J.D. from the University of Pittsburgh School of Law and an M.B.A. from Carnegie Mellon University, where he earned the Robert S. Sullivan Award for Distinguished Community Service. In addition to his duties at Archemix, Gregg is an Adjunct Professor of Corporate Finance at the F.W. Olin Graduate School of Business at Babson College. 
Page Bouchard, D.V.M., D.A.C.V.P., Senior Vice President, Discovery and Preclinical Development
Page joined Archemix Corp. in November 2004 and currently heads non-clinical R&D. Page has extensive experience in the area of preclinical drug discovery and development. Prior to joining Archemix he was Vice President of Drug Safety Evaluation at Millennium Pharmaceuticals. In this position, Page led the preclinical Drug Safety and Pathology organization, leading development projects to critical clinical and regulatory milestones. Prior to joining Millennium, Page was Assistant Vice President of Pathology at Wyeth, heading the discovery support pathology, toxicologic pathology, clinical pathology and toxicogenomics efforts. Page has over 12 years of pharmaceutical and biotechnology experience working on a diverse range of product types including recombinant human proteins and antibodies, small molecules and medical devices. He has been intimately involved in the successful filing of dozens of INDs and several NDAs for products in a wide range of therapeutic applications, and has published over 28 articles, book chapters and abstracts. He received a bachelor's degree from Wesleyan University and a D.V.M. from Tufts University Veterinary School. He trained in veterinary pathology at Cornell Veterinary School and is Board certified in veterinary pathology by the American College of Veterinary Pathologists. Page currently serves on the executive committee of the Society of Toxicologic Pathologists. 
Jim Gilbert, M.D., Senior Vice President, Chief Medical Officer
Jim joined Archemix in September 2006 and is responsible for all clinical and regulatory functions. Before his appointment at Archemix, Jim spent three years with Millennium Pharmaceuticals, most recently as the Vice President of Clinical Development, Cardiovascular/Inflammation. Prior to Millennium, Jim worked at Boehringer Ingelheim Pharmaceuticals Inc., holding numerous positions including Director, Clinical Research, Cardiology. He began his career with Bayer Corporation. Before joining the pharmaceutical industry, Jim held positions as an instructor in the Department of Pharmacology at the University of Connecticut School of Medicine and as a Staff Physician at St. Mary's Hospital in Waterbury, Connecticut. Jim earned an M.D. from the University of Connecticut School of Medicine and a B.S. in Molecular Biophysics and Biochemistry from Yale University. 
John Harre, J.D., Vice President, Intellectual Property and Legal Affairs
John joined Archemix in June 2002. John has extensive experience in identifying, obtaining, protecting and maximizing intellectual property in the biotechnology and life sciences sectors. Specific areas of expertise include strategic counseling; development and implementation of worldwide patent strategies; negotiations and drafting complex agreements; providing legal advice on various intellectual property and related matters; advising on FDA-related issues; and all aspects of patent, copyright and trademark litigation. Before joining Archemix, John was a partner in the biotechnology division of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo’s Intellectual Property Section in Boston. Earlier in his legal career, John was a member of the biotechnology patent law divisions at Fish & Richardson in Boston and Sidley, Austin, Brown & Wood in Dallas. John’s undergraduate and graduate work at the University of Missouri and Tennessee, respectively, focused on Biology and Molecular Biology. He received his J.D. from Pierce Law, specializing in intellectual property law. Prior to law school, John spent several years working at various academic, government sponsored and commercial institutions. James McArdle, Ph.D., Vice President , Chemistry, Manufacturing, and Controls
Jim has almost 25 years of pharmaceutical development experience, specifically in the areas of analytical chemistry, quality control, formulation development and manufacturing, and clinical supplies management. During his career, Jim has contributed directly to the commercialization of several pharmaceutical products. He also has served on a number of committees for the Pharmaceutical Research and Manufacturers of America and for the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human User (ICH). Before his appointment at Archemix, Jim spent almost seven years with Isis Pharmaceuticals, most recently as the Vice President of the Quality Assurance Department. In this position, he was responsible for FDA interaction, compliance, and third party management. Prior to this role, he served for six years as the Vice President of Analytical Development and Quality Control at Isis, where he directed significant advancements in oligonucleotide analytical chemistry methods. Prior to Isis, Jim worked for 16 years in a variety of capacities in analytical chemistry at SmithKline Beecham Pharmaceuticals. He received his Ph.D. in chemistry from the California Institute of Technology and his bachelor’s degree in chemistry from Brown University. Jim was a National Institutes of Health Postdoctoral Fellow at the University of California, Berkeley. 
Robert Schaub, Ph.D., Vice President, Pre-clinical Discovery
Bob has over 25 years of experience in drug discovery and pre-clinical development and is a world-class expert in cardiovascular disease biology. Before his appointment at Archemix, Bob spent 16 years with Genetics Institute and Wyeth Pharmaceuticals, most recently as the Assistant Vice President for Cardiovascular and Metabolic Diseases. In this position he led a research group that identified new disease targets and implemented drug discovery programs and advance molecules to Development Candidate status. During his tenure at Genetics Institute and Wyeth Pharmaceuticals, Bob held numerous other research positions where he had direct responsibility for research programs in inflammation, immunology, oncology, cardiovascular and musculoskeletal diseases. Bob began his career with The Upjohn Company. He received a bachelor's degree in biology from the University of Nevada and a Ph.D. from Washington State University. 
Chuck Wilson, Ph.D., Vice President, Alliance Management
Chuck currently serves as Vice President of Alliance Management and is responsible for initiating and implementing strategic collaborations with pharmaceutical and biotech partners to develop aptamer therapeutics. Recently, these efforts have led to productive partnerships with companies such as Takeda, Pfizer, Merck Serono, and élan. In addition, he oversees technology acquisition efforts to strengthen Archemix’s technology position in aptamers. These efforts have recently yielded strategic alliances with companies such as Isis Pharmaceuticals and SomaLogic in which Archemix has gained access to these partners’ broad technologies for therapeutic applications. In his most recent previous role, Dr. Wilson served as Archemix’s Chief Technology Officer where he was responsible for development of the aptamer therapeutic platform technology and for advancing therapeutic programs from target nomination into pre-clinical development. Prior to founding Archemix in 2001, Dr. Wilson was Associate Professor of Molecular, Cellular, and Developmental Biology at the University of California, Santa Cruz. At Santa Cruz, he established a center for x-ray crystallographic studies of RNA and his group solved the first crystal structures of aptamers bound to their small molecule targets. Chuck has received several awards in recognition of his scientific accomplishments including the Science and Engineering Fellowship of the David and Lucille Packard Foundation and a prestigious CAREER award from the National Science Foundation. |
|
